ADVANCED SOLID TUMORS

This early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will …

This study tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific change in the PI3K gene. The trial has two parts: first, finding the safest dose of OKI-219 alone, then testing it in combination with other cancer drugs. About 2…

This early-stage study tests a new drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors or…

This study tests an experimental drug called marlotamig (REGN7075) alone or with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 933 adults with a…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and s…

This study is for people with advanced solid tumors that have not responded to standard treatments. It tests a new drug called CKD-512, given alone or with another drug (pembrolizumab), to find safe doses and see how the body handles it. The goal is to control the disease, not cu…

This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment involves taking immune cells from the patient's tumor, boosting them in the lab to make them stronger, and then giving…

This study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 adults whose cancer has worsened after stan…

This study tests a new drug called RMC-6236 in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 754 people will take part, and the drug is…

This early-stage trial tests a new drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug works by targeting a protein called nectin-4 found on many cancer cells. The main goals are to check safety and see if the drug can sh…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancers) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop the…

This early-stage study tests a new drug, SIM0505, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 414 people will take part across multiple c…

This study tests a new drug called LCB84, which targets a protein (TROP2) on cancer cells, for people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or with another drug that boosts the immune system. The goal is to find sa…

This study tests a new medicine called SNV4818 for people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest and most effective dose, either alone or with other cancer drugs. About 320 participants will take part in this early-p…

This study tests a new drug called SPH4336, either alone or with another drug called cadonilimab, in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow or stop tumor growth. About 63 adults with advanced cancers, incl…

This early-phase study tests a new drug called AK146D1 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two targets on cancer cells to deliver a toxic payload directly. The main goals are to check safety and fi…